Clinical Trial of AC105 (Mg/PEG) for Treatment of Acute Spinal Cord Injury (SCI). Phase 2

Abstract

Acorda Therapeutics, Inc. is developing the polymer formulation of magnesium, known as AC-105, for the treatment of acute spinal cord injury. This trial is partially supported by the funds from this Department of Defense Broad Agency Announcement for Extramural Medical Research grant. The primary hypothesis of this proposed study is that treatment of people with acute SCI with AC-105 will result in greater normalization of CNS Mg than treatment with MgCl2 or saline solutions and potentially improve neurological outcome from injury.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2013
Accession Number
ADA599938

Entities

People

  • Andrew Blight

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Brain
  • Brain Injuries
  • Central Nervous System
  • Clinical Trials
  • Data Management
  • Department Of Defense
  • Health Services
  • Magnesium
  • National Governments
  • Nervous System
  • Saline Solution
  • Sodium Hydroxide
  • Spinal Cord
  • Spinal Injuries
  • Therapy
  • United States

Fields of Study

  • Medicine

Readers

  • Neuroscience
  • Technical Research and Report Writing.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.